FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapy.

Abstract

On February 16, 2024, the FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Lifileucel is the first tumor-derived T-cell therapy approved by the FDA. In the pivotal cohort of the phase 2 single-arm, trial, Study C-144-01, that served as the basis for approval, the objective response rate (ORR) among patients treated with lifileucel within FDA-approved dose range (7.5 x 109 - 72 x 109 viable cells, n=73) in the primary efficacy cohort was 31.5% (95% CI: 21.1%-43.4%), including 3 (4.1%) complete responses and 20 (27.4%) partial responses. The median duration of response was not reached (95% CI: 4.1 months-not reached). Among the responders (n=23), 56.5%, 47.8%, and 43.5% maintained durable responses at 6, 9, and 12 months, respectively. Among all patients who received lifileucel (N=156), 95.5% of patients experienced at least one Grade 3 treatment-emergent adverse event (TEAE) and 87.8% experienced at least one Grade 4 TEAE. Lifileucel labeling includes a Boxed Warning for treatment-related mortality, prolonged severe cytopenia, severe infection, cardiopulmonary impairment, and renal impairment.